Bioinspired Approaches to Engineer Antithrombogenic Medical Devices for Vascular Intervention

• Published in: Arteriosclerosis, thrombosis, and vascular biology Vol. 43; no. 6; pp. 797 - 812
• Main Authors: Hong (홍준기), Jun Ki, Waterhouse, Anna
• Format: Journal Article
• Language: English
• Published: United States Lippincott Williams & Wilkins 01.06.2023
• Subjects: Blood Coagulation; Fibrinolytic Agents - adverse effects; Humans; Thrombosis - etiology; Thrombosis - prevention & control; biomimetic materials; thrombosis; inventions; biomedical technology; biocompatible materials; technology assessment, biomedical; embolism
• ISSN: 1079-5642; 1524-4636; 1524-4636
• DOI: 10.1161/ATVBAHA.122.318238

Medical devices form a critical component of health care systems for treating and maintaining patient health. However, devices exposed to blood are prone to blood clotting (thrombosis) and bleeding complications leading to device occlusion, device failure, embolism and stroke, and increased morbidity and mortality. Over the years, developments in innovative material design strategies have been made to help reduce the occurrence of thrombotic events on medical devices, but complications persist. Here, we review material and surface coating technologies that have taken bioinspiration from the endothelium to reduce medical device thrombosis, either by mimicking aspects of the glycocalyx to prevent adhesion of proteins and cells to the material surface or mimicking the bioactive function of the endothelium through immobilized or released bioactive molecules to actively inhibit thrombosis. We highlight newer strategies that take inspiration from multiple aspects of the endothelium or are stimuli responsive, only releasing antithrombotic biomolecules when thrombosis is triggered. Emerging areas of innovation target inflammation to decrease thrombosis without increasing bleeding, and interesting results are coming from underexplored aspects of material properties, such as material interfacial mobility and stiffness, which show that increased mobility and decreased stiffness are less thrombogenic. These exciting new strategies require further research and development before clinical translation, including consideration of longevity, cost, and sterilization, but show capacity for the development of more sophisticated antithrombotic medical device materials.